# Insulet Corporation – Consensus ‘buy’ rating and 13.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-13.8-upside-potential/4121134877
- Published: 2023-12-01T12:33:15+00:00
- Author: Charlotte Edwards

**Insulet Corporation** which can be found using ticker (PODD) now have 18 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between $270.00 
and $163.00 suggesting an average Analsyt target price of $214.94. Given that the
stocks previous close was at $188.92 this is indicating there is a potential upside
of 13.8%. The 50 day MA is $156.16 while the 200 day moving average is $246.18. 
The market capitalization for the company is 13.20B. The stock price for the company
is currently $189.09 USD

 The potential market cap would be $15,022,249,821 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 109.94, revenue per share of $22.35
and a 2.36% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: